JMP Securities analyst Jason Butler lowered the firm’s price target on GH Research to $39 from $50 and keeps an Outperform rating on the shares following the Q4 earnings report. GH Research reported Q4 financial results and provided a corporate update, reiterating that the Phase 2b trial in treatment resistant depression remains on track to complete in 3Q24 with results in 4Q24, and that it has initiated preclinical studies requested by the Food and Drug Administration to address the clinical hold, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GHRS:
- GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
- GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
- EPO grants GH Research patent with claims directed to 5-MeO-DMT for MDD/TRD